Table 2: Prospective trials of hypofractionated external-beam radiotherapy (5 fractions).

AuthorNo. of patientsType of studyPatient
characteristics
NCCN risk group
HYPO FX
Total dose(Gy)/fractional dose(Gy)
Median
follow up
(months)
PSA control
Late GU toxicity
Late GI toxicity

Madsen et al. [53, 54]40Phase I/IILow risk33.5/6.76093%*at 5 years12.5%
2.5%
Gr-2
Gr-3
12.5%
0%
Gr-2
Gr-3

Tang et al. [55]30Phase I/IILow risk
35/71213%
0%
Gr-2
Gr-3
7%
0%
Gr-2
Gr-3

King et al. [56, 57]67Phase IILow risk36.25/7.253294%*at 4 years3%
5%
Gr-2
Gr-3
2%
0%
Gr-2
Gr-3

McBride et al. [58]45Phase ILow risk36.25/7.25
37.5/7.5
44.598%* at 3 years17%
2%
Gr-2
Gr-3
7%
5%
Gr-2
Gr-3

Boike et al. [59]45Phase ILow-Intermediate risk45/9
47.5/9.5
50/10
12–30100%*9%
4%
Gr-2
Gr-3
4%
0%
2%
Gr-2
Gr-3
Gr-4
Late toxicityLate toxicity
after 90 daysafter 90 days

No.: Number, HYPO FX: hypofractionation, STD FX: standard, Gy: Gray, FX: fractionation, *: by Phoenix definition, NS: not significantly different, GS: Gleason’s score.